NASDAQ:AMED Amedisys (AMED) Stock Forecast, Price & News $77.31 +0.56 (+0.73%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$76.18▼$77.6050-Day Range$69.79▼$81.0652-Week Range$69.36▼$131.32Volume163,500 shsAverage Volume911,022 shsMarket Capitalization$2.52 billionP/E Ratio22.47Dividend YieldN/APrice Target$108.94 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Amedisys MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside40.9% Upside$108.94 Price TargetShort InterestBearish8.20% of Float Sold ShortDividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews Sentiment0.98Based on 2 Articles This WeekInsider TradingSelling Shares$510,628 Sold Last QuarterProj. Earnings Growth9.41%From $4.25 to $4.65 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.87 out of 5 starsMedical Sector38th out of 1,009 stocksHome Health Care Services Industry4th out of 7 stocks 4.2 Analyst's Opinion Consensus RatingAmedisys has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 7 buy ratings, 6 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $108.94, Amedisys has a forecasted upside of 40.9% from its current price of $77.31.Amount of Analyst CoverageAmedisys has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.20% of the float of Amedisys has been sold short.Short Interest Ratio / Days to CoverAmedisys has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Amedisys has recently increased by 21.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmedisys does not currently pay a dividend.Dividend GrowthAmedisys does not have a long track record of dividend growth. Previous Next 5.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmedisys has received a 82.47% net impact score from Upright. Amedisys seems to create the most significant positive value in categories "Jobs", "Meaning & joy", and "Taxes". The positive contribution in the "Meaning & joy" impact category is mostly driven by its "Private hospice care", "Private speech therapy services", and "Private occupational physiotherapy services" products. See details.Environmental SustainabilityThe Environmental Impact score for Amedisys is -0.61. Previous Next 2.8 News and Social Media Coverage News SentimentAmedisys has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Amedisys this week, compared to 4 articles on an average week.Search Interest13 people have searched for AMED on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Amedisys to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amedisys insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $510,628.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Amedisys is held by insiders.Percentage Held by Institutions96.17% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Amedisys are expected to grow by 9.41% in the coming year, from $4.25 to $4.65 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amedisys is 22.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.41.Price to Earnings Ratio vs. SectorThe P/E ratio of Amedisys is 22.47, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 143.21.Price to Earnings Growth RatioAmedisys has a PEG Ratio of 2.16. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmedisys has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amedisys (NASDAQ:AMED) StockAmedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The High Acuity Care segment includes providing home care recovery for high acuity patients on either a full risk or limited risk basis. The company was founded in 1982 and is headquartered in Baton Rouge, LA.Read More Receive AMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter. Email Address AMED Stock News HeadlinesMay 26, 2023 | americanbankingnews.comAmedisys (NASDAQ:AMED) Coverage Initiated at StockNews.comMay 21, 2023 | thestreet.comAmedisys CEO Explains Why His Home Health Care Business Is BoomingMay 30, 2023 | Edge On The Street (Ad)Is Graphite the New Lithium?Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.May 20, 2023 | americanbankingnews.comAmedisys, Inc. (NASDAQ:AMED) Receives Consensus Rating of "Hold" from AnalystsMay 17, 2023 | americanbankingnews.comAmedisys (NASDAQ:AMED) Receives New Coverage from Analysts at StockNews.comMay 17, 2023 | americanbankingnews.comAmedisys, Inc. (NASDAQ:AMED) Short Interest UpdateMay 11, 2023 | msn.comAmedisys's Return On Capital Employed OverviewMay 10, 2023 | msn.comTD Cowen Maintains Amedisys (AMED) Market Perform RecommendationMay 30, 2023 | Edge On The Street (Ad)The Graphite Shortage Story You're Not Being ToldGraphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security. May 10, 2023 | americanbankingnews.comAmedisys, Inc. (NASDAQ:AMED) Forecasted to Earn Q2 2023 Earnings of $1.11 Per ShareMay 9, 2023 | americanbankingnews.comSVB Securities Cuts Amedisys (NASDAQ:AMED) Price Target to $81.00May 8, 2023 | americanbankingnews.comAmedisys (NASDAQ:AMED) Price Target Cut to $81.00 by Analysts at SVB SecuritiesMay 7, 2023 | americanbankingnews.comAmedisys (NASDAQ:AMED) Price Target Cut to $97.00 by Analysts at Truist FinancialMay 6, 2023 | americanbankingnews.comAmedisys (NASDAQ:AMED) PT Lowered to $88.00 at BarclaysMay 4, 2023 | finance.yahoo.comAmedisys (AMED) Q1 Earnings Beat Estimates, Margins DipMay 4, 2023 | americanbankingnews.comAmedisys, Inc. (NASDAQ:AMED) Sees Large Growth in Short InterestMay 4, 2023 | finance.yahoo.comAmedisys (AMED) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 3, 2023 | finance.yahoo.comOption Care Health and Amedisys to Combine Creating a Leading, Independent Platform for Home and Alternate Site CareMay 3, 2023 | finance.yahoo.comAMEDISYS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES 2023 GUIDANCEMay 1, 2023 | americanbankingnews.comAmedisys (AMED) to Release Quarterly Earnings on WednesdayApril 30, 2023 | americanbankingnews.comAmedisys, Inc. (NASDAQ:AMED) Receives $112.33 Consensus Price Target from BrokeragesApril 23, 2023 | americanbankingnews.comAmedisys (NASDAQ:AMED) Research Coverage Started at Cantor FitzgeraldApril 20, 2023 | finance.yahoo.comAmedisys Announces First Quarter 2023 Earnings Release and Conference Call DateApril 16, 2023 | americanbankingnews.comAmedisys (NASDAQ:AMED) Price Target Lowered to $115.00 at Truist FinancialApril 14, 2023 | finance.yahoo.comAmedisys (AMED) New Buyouts Aid Growth, CMS Ruling UnfavorableApril 14, 2023 | msn.comTruist Securities Maintains Amedisys (AMED) Buy RecommendationApril 12, 2023 | finance.yahoo.comAn Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% UndervaluedSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter. Email Address AMED Company Calendar Last Earnings5/04/2023Today5/30/2023Next Earnings (Estimated)7/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Home health care services Sub-IndustryHealth Care Services SectorMedical Current SymbolNASDAQ:AMED CUSIP02343610 CIK896262 Webwww.amedisys.com Phone(225) 292-2031Fax225-292-8163Employees20,000Year Founded1982Price Target and Rating Average Stock Price Forecast$108.94 High Stock Price Forecast$165.00 Low Stock Price Forecast$81.00 Forecasted Upside/Downside+40.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$3.44 Trailing P/E Ratio22.47 Forward P/E Ratio18.19 P/E Growth2.16Net Income$118.61 million Net Margins5.02% Pretax Margin6.77% Return on Equity14.35% Return on Assets7.89% Debt Debt-to-Equity Ratio0.33 Current Ratio1.15 Quick Ratio1.15 Sales & Book Value Annual Sales$2.22 billion Price / Sales1.13 Cash Flow$7.25 per share Price / Cash Flow10.67 Book Value$34.06 per share Price / Book2.27Miscellaneous Outstanding Shares32,560,000Free Float31,875,000Market Cap$2.52 billion OptionableOptionable Beta1.02 Social Links Key ExecutivesRichard M. AshworthPresident & Chief Executive OfficerScott G. GinnChief Operating & Financial Officer & EVPMichael P. NorthChief Information OfficerDenise M. BohnertChief Compliance OfficerKendra KimmonsVice President-Marketing & CommunicationsKey CompetitorsChemedNYSE:CHEAdaptHealthNASDAQ:AHCOAddus HomeCareNASDAQ:ADUSOption Care HealthNASDAQ:OPCHCorcept TherapeuticsNASDAQ:CORTView All CompetitorsInsiders & InstitutionsLegato Capital Management LLCBought 2,368 shares on 5/25/2023Ownership: 0.029%Capital Impact Advisors LLCSold 2,261 shares on 5/23/2023Ownership: 0.014%Toroso Investments LLCBought 3,250 shares on 5/23/2023Ownership: 0.010%Seaport Global Advisors LLCBought 279 shares on 5/23/2023Ownership: 0.008%Ameriprise Financial Inc.Sold 270,594 shares on 5/22/2023Ownership: 2.494%View All Insider TransactionsView All Institutional Transactions AMED Stock - Frequently Asked Questions Should I buy or sell Amedisys stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 2 sell ratings, 6 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares. View AMED analyst ratings or view top-rated stocks. What is Amedisys' stock price forecast for 2023? 15 equities research analysts have issued 12 month target prices for Amedisys' stock. Their AMED share price forecasts range from $81.00 to $165.00. On average, they predict the company's stock price to reach $108.94 in the next twelve months. This suggests a possible upside of 40.9% from the stock's current price. View analysts price targets for AMED or view top-rated stocks among Wall Street analysts. How have AMED shares performed in 2023? Amedisys' stock was trading at $83.54 at the beginning of 2023. Since then, AMED stock has decreased by 7.5% and is now trading at $77.31. View the best growth stocks for 2023 here. When is Amedisys' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023. View our AMED earnings forecast. How were Amedisys' earnings last quarter? Amedisys, Inc. (NASDAQ:AMED) announced its quarterly earnings results on Thursday, May, 4th. The health services provider reported $1.00 EPS for the quarter, topping analysts' consensus estimates of $0.86 by $0.14. The health services provider earned $556.39 million during the quarter, compared to analyst estimates of $558.98 million. Amedisys had a trailing twelve-month return on equity of 14.35% and a net margin of 5.02%. The business's revenue for the quarter was up 2.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.23 earnings per share. What ETFs hold Amedisys' stock? ETFs with the largest weight of Amedisys (NASDAQ:AMED) stock in their portfolio include Harbor Health Care ETF (MEDI), Simplify Health Care ETF (PINK), SPDR S&P Health Care Services ETF (XHS), First Trust Health Care AlphaDEX Fund (FXH), SRH U.S. Quality ETF (SRHQ), Distillate Small/Mid Cash Flow ETF (DSMC), iShares U.S. Healthcare Providers ETF (IHF) and BlackRock Future Health ETF (BMED). How will Amedisys' stock buyback program work? Amedisys declared that its board has initiated a stock buyback program on Wednesday, August 4th 2021, which authorizes the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 1.2% of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued. What guidance has Amedisys issued on next quarter's earnings? Amedisys issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share guidance of $4.14-$4.36 for the period, compared to the consensus earnings per share estimate of $4.25. The company issued revenue guidance of $2.25 billion-$2.27 billion, compared to the consensus revenue estimate of $2.26 billion. What is Paul B. Kusserow's approval rating as Amedisys' CEO? 478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend. What other stocks do shareholders of Amedisys own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD). What is Amedisys' stock symbol? Amedisys trades on the NASDAQ under the ticker symbol "AMED." Who are Amedisys' major shareholders? Amedisys' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.33%), Wellington Management Group LLP (7.98%), JPMorgan Chase & Co. (6.13%), Riverbridge Partners LLC (4.69%), Mackenzie Financial Corp (3.20%) and State Street Corp (2.83%). Insiders that own company stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Michael Paul North, Richard A Lechleiter, Scott G Ginn and Sharon Brunecz. View institutional ownership trends. How do I buy shares of Amedisys? Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amedisys' stock price today? One share of AMED stock can currently be purchased for approximately $77.31. How much money does Amedisys make? Amedisys (NASDAQ:AMED) has a market capitalization of $2.52 billion and generates $2.22 billion in revenue each year. The health services provider earns $118.61 million in net income (profit) each year or $3.44 on an earnings per share basis. How many employees does Amedisys have? The company employs 20,000 workers across the globe. How can I contact Amedisys? Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163. This page (NASDAQ:AMED) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedisys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.